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Introduction
Lymphatic filariasis (LF) is a debilitating
vector-borne disease predominantly
caused by the helminths Wuchereria bancrofti
and Brugia malayi [1,2]. Endemic in 72
countries, LF is responsible for 5.9 million
DALYs lost and is implicated as the
second leading cause of disability world-
wide by the World Health Organization
(WHO) [3–5]. Although 70% of those
infected do not exhibit symptoms, almost
all persons infected have subclinical dam-
age to the lymphatic vessels [6,7]. An
estimated 40 million people are symptom-
atic with the predominant morbidities
associated with LF: lymphedema and/or
hydrocele [8].
In recognition of the worldwide burden
of LF, in 1997, the World Health
Assembly passed the resolution WHA
50.29 calling for collaborative efforts by
member states to eliminate the disease as a
public health problem [9]. In 2000, the
Global Programme to Eliminate Lym-
phatic Filariasis (GPELF) was formed in
response to the WHA resolution and
aimed to eliminate the disease by 2020.
The program adopted a two-pronged
strategy: (1) to interrupt transmission of
the causal parasite and (2) to alleviate
morbidities associated with the disease
[10]. The two pillars of the GPELF’s
strategy form the basic framework for any
successful LF program.
Togo is one of the 34 African countries
endemic for lymphatic filariasis and is
surrounded by the endemic countries of
Benin, Ghana, and Burkina Faso [11].
The National Program to Eliminate Lym-
phatic Filariasis (NPELF) was founded in
2000 and is one of the few LF programs
that address the dual goals of the global
elimination program on a national scale.
Togo is the first sub-Saharan country to
achieve probable interruption of transmis-
sion and to move to the post-MDA
surveillance phase as defined by the
WHO [12]. Here we describe the ele-
ments that proved successful in the
national strategy to address LF in Togo.
Assessing the Burden
Infection
The Togolese Ministry of Health (MoH)
used the Rapid Assessment of Geograph-
ical Distribution of Filariasis (RAGFIL)
methodology, developed by the Special
Programme for Research and Training in
Tropical Diseases (TDR), to assess coun-
trywide infection [11,13]. National map-
ping was performed in two stages [11].
Thirty-seven villages representing 17 of
Togo’s 35 health districts (with 5 in Lomé,
the capital city) participated in the initial
mapping in 1998. In 2000, an additional
24 villages were selected using the WHO’s
Health Mapper software version 3.0 to
ensure that the whole country was covered
[11]. The distance between two mapped
villages in the final map was never more
than 50 km; each selected village repre-
sents the state of the transmission in a
radius of 25 km. The tests for both stages
entailed collection of 100 ml of capillary
blood from a person’s fingertip and
subsequent testing using rapid immuno-
chromatographic tests (ICT) (AMRAD,
Townsville, Queensland, Australia). The
ICT used is specific for W. bancrofti and
detects the presence of circulating filarial
antigen (CFA) [14]. From the 2009
samples collected in 61 villages, 89 persons
(1.8%) were ICT positive. Seven districts
were classified as endemic because the
prevalence of ICT positivity exceeded the
1% threshold [15,16] (Figure 1). Several
districts along the Togo–Benin border in
the south were unexpectedly classified as
nonendemic although they were endemic
in the past and currently have a high
prevalence of LF morbidity [17]. Possibly,
LF transmission was interrupted by inten-
sive vector-control methods implemented
in the area by the malaria program in the
1970s.
Morbidity
As accurate estimates of the national
burden of LF morbidity are difficult to
obtain, Mathieu and others described
different methods to obtain LF morbidity
prevalence in Togo [18]. Prevalence
estimates for lymphedema and hydrocele
were calculated based on information
collected during LF mapping and from
sentinel sites. Morbidity questions were
also added onto three 30-cluster drug
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Figure 1. Districts endemic for lymphatic filariasis during the initial mapping.
doi:10.1371/journal.pntd.0002080.g001
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coverage surveys that were conducted in
six of Togo’s endemic districts and onto a
nationwide malaria bed net coverage
survey.
Sentinel site data, cluster survey data,
and the malaria bed net coverage survey
data detected a hydrocele prevalence of
0.61% (95% CI 0.00–1.41), 0.63% (95%
CI 0.20–1.06), and 2.6% (95% CI 1.8–
3.4), respectively [19]. These same sources
revealed a lymphedema prevalence of
0.80% (95% CI 0.00–1.98), 0.17% (95%




Shortly after the mapping, mass drug
administration (MDA) campaigns were
launched. All of Togo’s LF districts are
coendemic for onchocerciasis, and the
communities with less than 2,000 inhabi-
tants have been undergoing an annual or
biannual MDA with ivermectin since the
late 1980s [20,21]. The NPELF modified
the distribution system established by the
onchocerciasis program through the coad-
ministration of albendazole with ivermec-
tin. The timings of the campaigns were
synchronized since LF elimination distri-
butions are required to be organized at the
same time in all endemic areas. The
geographic coverage in the districts was
also expanded to treat villages that were
not endemic for onchocerciasis or that had
a population above 2,000 inhabitants.
The processes of drug distribution and
reporting were facilitated by utilizing
Togo’s decentralized pyramidal health
structure. A single community health
worker (CHW) was selected to represent
every 300 people in the endemic districts.
As the first step toward calculating drug
needs, the CHWs visited their respective
households prior to each MDA in order to
count all inhabitants. The results of the
CHWs’ annual census were used by the
national coordinator to calculate drug
needs. The NPELF requested ivermectin
(Merck & Co., Inc., White House Station,
New Jersey, United States) and albenda-
zole (GlaxoSmithKline, Brentfort, United
Kingdom) from the Mectizan Donation
Program (MDP). Drug distribution fol-
lowed the reverse chain of reporting and
ended with house-to-house distribution by
the CHWs. As children under the age of
five are ineligible to receive the treatment,
the CHWs used a measuring stick to aid in
age estimation and excluded all children
with heights below 90 cm [22]. Seriously
ill individuals and pregnant women were
also excluded from the treatment. The
number of people who ingested the drugs
was recorded by the CHWs. This data was
sent through the appropriate channels
back to the NPELF and reported coverage
rates calculated.
The first LF MDA was held in the
district of Binah in 2000, and within three
years, distributions scaled up to all seven
endemic districts. Since 2004, reported
drug coverage in each district has exceed-
ed 80% of the total population (Table 1).
Coverage levels submitted by the CHWs
were verified by a coverage survey per-
formed in 2004 (described below). Scaling
down started in 2008 and in 2009 when
the final MDAs were organized in the
districts of Tone and Doufelgou.
Lymphedema Management
In collaboration with the CDC and
funded by IMA World Health-USAID,
the Togo MoH engaged in an innovative
approach to implement WHO-recom-
mended lymphedema management tech-
niques on a national scale (including the
nonendemic districts). The lymphedema
management program began in 2007 by
training at least one staff member in each
of the 570 health facilities in lymphedema
education and care. This was followed by
an awareness campaign to inform the
population that care for ‘‘swollen legs’’
was available. Patients were trained in self-
care by using WHO education materials
that were locally adapted, and support
structures for patients were created. The
program sought to ensure sustainability
beyond external funding by being low in
cost and by including lymphedema treat-
ment in standard medical training pro-
grams.
Over the course of one year, the
lymphedema management program scaled
up to achieve national coverage. A total of
1,083 patients were enrolled into the
program; approximately 30% of whom
lived in nonendemic districts. An evalua-
tion of the program, which was conducted
three years after the launch, showed that
62% of the persons with a swollen leg,
regardless of the cause or severity (revers-
ible swelling was included), were still
enrolled in the program.
Hydrocele Surgeries
Another key element to success was
participation in the multicountry West
African LF Morbidity Project. Multiple
workshops on the current WHO-recom-
mended surgical techniques for hydrocele
were held for district-level surgeons on an
annual basis from 2005 to 2007 and then
again in 2009. Following each workshop,
surgical campaigns were conducted [23],
along with a series of national campaigns
to increase the availability of hydrocelec-
tomies to the affected population.
Since the program’s inception, 24
district surgeons have participated in the
surgical trainings. During the three cam-
paigns that ran from 2005 to 2006, 257
hydrocelectomies were performed. In
2007 and 2008, 215 hydrocelectomies
were performed with additional financial
assistance from Health & Development
International (HDI).
Monitoring and Evaluation
The success of the NPELF was partially
due to the rigorous monitoring and
evaluation system.
MDA Coverage
Following each annual drug distribu-
tion, reported drug coverage was collected
using the participation tally submitted by
the CHWs. The denominator used was
the total population (annual census), which
was calculated by the CHWs prior to each
MDA. In each, the WHO’s goal of 70%
drug coverage was achieved, and since
2004, all districts’ reported drug coverage
has exceeded 80% (see Table 1). In 2004,
coverage surveys were conducted with
technical assistance from the CDC using
the probability proportional to estimated
size (PPES) 30-cluster design, and the
reported coverage was validated [16].
Impact of MDA
A system of sentinel and spot-check sites
was set up in the endemic districts in order
to evaluate the impact of the MDA
campaigns on microfilaremia. Seven sen-
tinel sites were initially selected; due to
budget constraints, the number of sites was
later trimmed to three sites. Each of these
three sites represented a cluster of districts.
After the baseline collection in 2000,
subsequent sentinel-site activities were
conducted before the third and fifth year
of MDA in each district. Blood samples
were collected from 500 people in each
sentinel site between the hours of 22:00
and 02:00. In adherence with WHO
guidelines [16], spot-check sites were also
selected from the endemic districts as an
additional monitoring mechanism prior to
the fifth round of MDA using a similar
testing methodology to the sentinel sites.
Between 2005 and 2009, 13 spot-check
sites were conducted from urban sites,
cross-border areas, and other locations
that were suspected to carry an elevated
risk for ongoing transmission.
The baseline results from the sentinel
sites indicated a microfilaremia prevalence
between 1% and 36%. Since 2004,
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microfilaria samples from the sentinel sites
(see Figure 2) and spot checks have all
been below 1%. Five of the seven districts
have consistently registered prevalence
levels of 0% in all sentinel and spot-check
sites. MDAs were halted in 2008 following
six to seven MDAs. Additional MDA
campaigns were conducted in 2009 in
two districts: i) in Tone, after seven MDAs,
where a prevalence of 2% was detected at
the spot-check site of Woriwouri, a village
in close proximity to endemic areas in
Burkina Faso and Ghana and ii) in
Doufelgou, where an additional MDA
was organized because, although preva-
lence level was reported at 0% in the
sentinel site after the third MDA, this
sentinel village was not assessed after the
fifth MDA. No detection of bancroftian
filaria was found after the subsequent
MDAs. The results from the sentinel and
spot-check sites indicate that nine years of
MDA campaigns have succeeded in re-
ducing levels of microfilaria in Togo to
0%, thus most likely achieving interrup-
tion of transmission.
Ongoing Surveillance
Togo is the first country to implement a
nationwide LF surveillance system. Imple-
mented in 2006, Togo put in place a
system to identify and track cases with
active infection. Forty laboratories were
selected throughout the country for inclu-
sion in surveillance activities. This system
utilized nocturnal thick blood smears for
malaria diagnosis, as they can concurrent-
ly be used to make LF diagnoses [24].
Participation in the surveillance system
required laboratory technicians to send all
slides with identified W. bancrofti, in
addition to ten randomly selected slides
per month, to the reference laboratory in
Lomé.
Within the first four years of the
surveillance system, 8,050 slides were
accrued by the reference laboratory and
two LF-positive slides were identified.
Both cases were followed up according to
a predetermined algorithm of action, and
no further positive cases followed. An
evaluation of the system showed that some
border areas were not as well covered. It
was decided to increase the coverage of
the surveillance system by implementation
of centralized ELISA-based testing for
antigenemia using filter-paper blood spots
collected in dispensaries (Figure 3). No
active transmission focus has been detect-
ed so far by the system.
Operational Research
Added components that contributed to
the success of the NPELF were several
operational research projects that further




As mentioned, operational research im-
plemented with the CDC’s assistance
resulted in the formation of Togo’s national
lymphedema program. One of the evalua-
tion tools was a cohort survey (2004–2010)
of 188 LF patients to assess impact. The
survey addressed indicators such as current
and previous treatment practices, quality of
life, economic factors, and overall program
impact among patients with lymphedema
[25]. Between the preprogram assessment
in 2007 and the assessment at the end of the
funding in 2010, the proportion of patients
(n = 107) who did not seek treatment or
sought traditional methods decreased from
30.8% to 2.8%. An increase of positive
treatment practices was also observed: the
practice of cleaning the limb increased from
10.3% to 92.5% and exercising increased
from 3.7% to 78.5%, (p,0.0001) (unpub-
lished data).
Transmission Assessment and Post-
treatment Surveillance
As the macrofilaremia in the sentinel
sites and spot-check sites were ,1%, the
NPELF conducted a 30-cluster survey to
establish interruption of disease transmis-
sion among children two and six years of
age. In May 2008, the cluster survey was
carried out with support from the Emory
University LF Support Center, Atlanta
following the WHO 2005 guidelines [16].
ICT card and blood spots for Og4C3
ELISA were performed. The ELISA
testing conducted by the CDC indicated
that all but one child was negative.
In 2006, the NPELF collaborated with
the MDP and the CDC to develop an
innovative ongoing national surveillance
system. Several sampling modalities, such
as using military recruits and blood banks,
were considered, but it was decided to
base the system on nocturnal thick smears
collected to diagnose malaria as described
above [24]. This surveillance system was
eventually taken over by the MoH as part
of the ongoing LF activities. With the
financial support of RTI/USAID, the
NPELF and the CDC evaluated this
system in 2010 and validated also the
initial mapping.
In 2012, the first post-MDA transmis-
sion assessment surveys (TAS) using the
WHO’s new guidelines [12] were con-
ducted in the seven districts grouped into
four evaluation units (EU). The results
suggested that all EUs passed as the
number of ICT-positive cases was below
the cut-off value of 18. The positive cases
included: eight cases in Tone-Kpendjal
EU, one case in Binah-Doufelgou EU,
four cases in Amouh-Haho EU, and no
cases in Kozah EU.
In order to confirm the absence of
recrudescence and prepare the country for
certification, the post-MDA surveillance
activities will continue until 2015. These
Table 1. Reported coverage for MDA in endemic districts of Togo (denominator = total population).
Therapeutic Coverage (%)
District MDA1 MDA2 MDA3 MDA4 MDA5 MDA6 MDA7 MDA8 MDA9
Amou 74 76 81 86 85 86 85 – –
Binah 81 78 88 86 87 87 84 86 –
Doufelgou 80 88 85 85 86 87 87 – 87
Haho 79 74 83 82 85 86 85 – –
Kozah 84 87 87 87 87 87 – – –
Kpendjal 65 89 81 81 83 85 85 85 –
Tone 77 75 81 82 84 84 85 84 84
Coverage is calculated out of total population in the area of distribution.
doi:10.1371/journal.pntd.0002080.t001
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activities include ongoing surveillance and
the implementation of the second and final
WHO-recommended TAS scheduled for
2015.
Other Research
In 2005, the NPELF also contributed to
guide the global integrated NTD program
by launching a three-year program sup-
ported by the CDC. The national NTD
program coordinators developed an inte-
grated NTD program during a one-year
preparation phase to elaborate integrated
tools and guidelines for an integrated
NTD program. The integrated areas
covered were mapping, baseline data,
MDA, health education, and monitoring
and evaluation. Thanks to a praziquantel
donation from the Schistosomiasis Control
Initiative (SCI), the integrated approach
was twice piloted in the district of Binah
and achieved good results. The coverage
rates were high, program managers ad-
hered to the concepts, and chances for
sustainability were believed to be strength-
ened by linking unfunded NTD programs
(STH, schistosomiasis) with well-funded
programs. Based on this success, the MoH
was able to secure funding for a national
scale-up.
Furthermore, the NPELF program con-
ducted operational research to validate
drug coverage surveys with assistance from
the MDP and the CDC. The accuracy of
the results of such surveys was tested one,
six, and 12 months after an MDA in Togo
in which three drugs (albendazole, iver-
mectin, and praziquantel) were distribut-
ed. Survey results indicated that the
respondents were able to accurately recall
if they took the drugs.
Advocacy and Fundraising
The main key to success in Togo was
the mixture of an opportunistic approach
from the NPELF combined with strategic
and generous partners. Since the 1990s,
Togo has been an underfunded country
due to the political climate and subsequent
digression from democracy [26,27]. How-
ever, the NPELF was initiated and carried
out thanks to financial and technical
support from Health & Development
International (HDI), a Norwegian NGO
which provided support during the first
nine years of the program [28]. HDI also
made the program visible and attractive to
new external partners such as LF program
support centers in Atlanta and Liverpool
and the CDC. This enabled the NPELF to
capitalize on the strength of partnerships
and networking and allowed them to
implement all the activities required for
the elimination of LF. In addition to HDI
funding, in 2000, the program was award-
ed a portion of the DFID grant through
the WHO. The collaboration with the
onchocerciasis control program facilitated
the reduction of the costs of drug distri-
bution and sustained high MDA coverage.
The collaboration with the national ma-
laria program resulted in submitting an
innovative joint malaria/LF proposal to
the Global Fund to Fight AIDS, Tuber-
culosis and Malaria (GFATM) that se-
cured five years of implementation fund-
ing for MDA and impact assessments.
Discussion
This paper describes not only the first
sub-Saharan LF program that probably
interrupted transmission, but demon-
strates that it is possible and essential for
morbidity programs to be codeveloped
along with the MDA campaigns in order
to fully address the burden of the disease
in endemic territories.
The ability to implement an LF national
program was not evident due to a variety
of embargoes that were placed on Togo in
the late 1990s. These embargoes kept the
country in a state of severe economic
stress. Although in this political climate LF
was not perceived as a health priority, the
dedication and endorsement of the con-
cept of LF elimination by the MoH has,
and continues to be, a critical factor in
setting up a successful program. For
example, during some years, the program
was unable to provide the small MDA
incentive of $3 to $6 USD per CHW
volunteer. Regardless, the CHWs distrib-
uted the medications, motivated by the
Figure 2. Progression of microfilaremia in sentinel sites in the endemic districts of Togo following subsequent mass drug
administrations.
doi:10.1371/journal.pntd.0002080.g002
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spirit of the collaborative environment
created by the NPELF. Highly motivated
CHWs also facilitated high compliance in
the communities where LF was either
largely unknown or not perceived as a
health problem.
A factor contributing to success was the
fact that the MoH used existing structures.
Indeed, the MDAs for LF elimination
were initiated using the preexisting struc-
ture of the community-directed ivermectin
treatment (CDTI) established by the
national onchocerciasis control program
[21]. The surveillance and M&E activities
in the Togo program required the MoH to
engage the decentralized clinical laborato-
ry network to conduct cost-effective im-
pact assessments. It also allowed the MoH
to establish robust relationships with
research institutions. The NPELF also
identified resources within Togo’s existing
health structure to implement lymphede-
ma and hydrocele management. It was
found that the decentralized health system
could be used to disseminate lymphedema
management training through multiple
layers of health staff and community
workers.
Additionally, the NPELF demonstrated
the ability to recognize and capture each
funding opportunity to implement all
components of the program. To date, the
NPELF remains the only LF program in
Africa that has been awarded financial aid
from the GFATM. The collaboration with
the CDC on several operational research
projects enabled the program to imple-
ment some crucial aspects of the elimina-
tion program such as morbidity manage-
ment and surveillance. It has also
increased the visibility of the program
and provided access to even more resourc-
es.
It is also important to point out that the
impact of this successful program is not
limited to only alleviating the filariasis
burden in Togo. The program was the
base for RTI/USAID funding for an
integrated NTD program resulting in
finalizing national mapping [29] and
implementing national schistosomiasis
Figure 3. Geographic coverage of the LF surveillance system, 2006–2007.
doi:10.1371/journal.pntd.0002080.g003
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and STH MDAs. The results of the
operational research projects and the
lessons learned by the NPELF are widely
discussed at international meetings and
shared with peers. The NPELF is also
assisting other countries in replicating the
lymphedema management pilot program
through the creation of a national mor-
bidity training manual that describes
program components and contains useful
information for implementing a national
morbidity management program in low-
resource settings [30]. This manual is
widely shared and is used by other
partners such as Handicap International
and the CDC Foundation to implement
programs in other countries (e.g., Benin
and Mali). Based on the Togo experience,
surveillance systems will be set up in two
additional African countries and the
program coordination is providing techni-
cal assistance to countries in the region.
The success of the NPELF in Togo
shows that lymphatic filariasis can be
effectively addressed in countries with
limited funds when cooperative efforts
combine with motivation and innovation.
Ministries of health play a critical role in
embracing the scaling up of program
activities, and new avenues for partner-
ships and funding must be vigorously
pursued. The main lesson learned is that
when developing a national disease elim-
ination strategy, a key component must be
putting forth the time and effort to build
strong collaborations among appropriate
partners. This networking with program
collaborators when combined with persis-
tent advocacy and fundraising was the
crucial component that permitted the
NPELF to address LF in Togo.
In conclusion, as summarized in
Table 2, the success of the National
Program to Eliminate Lymphatic Filariasis
in Togo was facilitated by charismatic,
innovative, and trustworthy program man-
agers able to i) timely identify issues and
solutions, ii) ensure visibility at the highest
levels of the MoH, iii) adopt an opportu-
nistic approach using existing health
interventions and a decentralized health
system to integrate LF activities, and most
importantly, iv) develop a variety of
partnerships and pioneering approaches
to mobilize resources for a synchronized
implementation of the twin-pillar strate-
gies as recommended by the GPELF. The
adoption of these approaches could aid
other countries that are not on target to
reach the 2020 LF elimination goal in sub-
Saharan Africa.
Way Forward
In agreement with the new guidelines of
the WHO [12], in 2010, the NPELF of
Togo entered into a five-years post-MDA
surveillance phase that will take the
country to the WHO’s independent veri-
fication of absence of the transmission in
2015. During this surveillance phase, the
lab-based surveillance will continue
throughout the country with an emphasis
on areas bordering endemic districts of the
three neighboring countries where the
MDAs are still ongoing. In addition, the
final TAS will be implemented in 2015 in
the seven previously identified endemic
districts. The current challenge is to
maintain momentum for adequate human
and financial resources allocation in order
to support the implementation of the
critical endgame activities. The program
coordination is closely working with the
Table 2. Determinants of success of the National Program to Eliminate Lymphatic Filariasis in Togo.
1. Strong sustained political commitment
- Enthusiastic and knowledgeable program coordinators who pushed the agenda at the highest level of the Ministry of Health
- Partners who gave visibility to the program at high level
2. Small burden of the disease
- Relatively small size of the country (total area = 56,785 sq km; total population = 6.9 million inhabitants)
- Limited burden (approximately 20% of the total population was at risk)
3. Establishment of a motivated, knowledgeable management team
- Strong and trustworthy coordinators who fully understood the program’s strategies and challenges and who were fully committed to partnership and innovation
- Coordinators were changed depending on needs of program
- Establishment of a three-prong team (not all full-time)
+ M&E focal person shared with other programs
+ lymphedema management focal person
+ hydrocele management focal person (surgeon, part-time adviser)
4. Flexible administration
- Easy access of the program coordinator to the highest level of the Ministry of Health
- Administration was willing to adapt to program’s needs: flexible system to obtain travel orders, money from the account
5. Integration with existing health interventions
- Easy access of the program coordinator to the highest level of the Ministry of Health
6. Innovative resources mobilization in an environment totally lacking local resources
- Jumped on all opportunities to get free health education emissions by the national television and local radios
- Joint malaria/LF proposal granted by the GFATM
- Accepted small research funds ($10,000 USD or up) to start innovative program
7. Very strong partnerships built up starting from no existing partnerships
- Internal partnerships (with community drug distributors, district health team, academic institutions, etc.)
- External partnerships (with GSK, Merck, MDP, HDI, LF support centers of Atlanta and Liverpool, CDC, IMA, GFATM)
doi:10.1371/journal.pntd.0002080.t002
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national malaria control program in order
to reach/maintain universal insecticide-
treated net coverage. Most importantly, it
is the desire to increase the net compliance
rate that was demonstrated to be a
problem in the Togolese communities
[31]. The morbidity control activities are
expected to be fully integrated within the
health system and are deemed to continue
providing care to patients even beyond the
verification target.
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